Q4 2025 Organogenesis Holdings Inc Earnings Call Transcript
Key Points
- Organogenesis Holdings Inc (ORGO) delivered record sales results in Q4 2025, exceeding the high end of their guidance range.
- Advanced wound care products saw an impressive 83% year-over-year sales growth.
- The company is making capital investments, including a new manufacturing and R&D center in Smithfield, Rhode Island, to support future growth.
- Organogenesis Holdings Inc (ORGO) is expanding its mission into new markets with the Renew program, which could transform treatment for knee osteoarthritis.
- The company has a strong cash position with $94.3 million in cash equivalents and no outstanding debt obligations as of December 30, 2025.
- Sales of surgical and sports medicine products declined by 2% year-over-year in Q4 2025.
- The company expects total net revenue to decline by 25% to 38% year-over-year for the full year 2026 due to clinician confusion and market disruptions.
- Significant clinician confusion has impacted utilization of PMA approved products in early 2026.
- Operating expenses increased by 39% year-over-year in Q4 2025, driven by higher SG&A expenses and non-recurring costs.
- The company anticipates a challenging first half of 2026 with a projected 50% revenue decline in Q1 due to CMS policy changes and market confusion.
Please stand by.
Welcome, ladies and gentlemen, to the fourth quarter and full year 2025 earnings conference call for Organogenesis Holding Inc. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risk and uncertainties that it could cause actual results to differ materially from those. Indicated, including the risk and uncertainties described in the company's filings with the Securities and Exchange Commission, including item 1A, risk factors of the company's most recent annual report and its subsequently filed quarterly report.
You are cautioned not to place undue reliance upon any forward-looking statements which speak only as of the date made, although it may voluntarily do so from time to time, the company undertakes no commitment
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
